Blueprint Medicines Co. (NASDAQ:BPMC) Receives Average Recommendation of “Moderate Buy” from Analysts

Blueprint Medicines Co. (NASDAQ:BPMC) has been given an average recommendation of “Moderate Buy” by the twenty brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $118.22.

A number of brokerages have weighed in on BPMC. Barclays boosted their price target on Blueprint Medicines from $75.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Monday, July 29th. Robert W. Baird raised their price target on Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. UBS Group assumed coverage on shares of Blueprint Medicines in a report on Thursday. They issued a “neutral” rating and a $88.00 price objective on the stock. Morgan Stanley raised their target price on shares of Blueprint Medicines from $110.00 to $115.00 and gave the stock an “equal weight” rating in a research note on Friday, July 12th. Finally, Oppenheimer upped their price target on shares of Blueprint Medicines from $114.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, July 8th.

Blueprint Medicines Trading Down 0.7 %

NASDAQ BPMC opened at $82.47 on Tuesday. Blueprint Medicines has a 12 month low of $47.66 and a 12 month high of $121.90. The company has a current ratio of 3.71, a quick ratio of 3.65 and a debt-to-equity ratio of 1.06. The stock has a 50 day moving average of $89.55 and a 200-day moving average of $98.53. The company has a market cap of $5.16 billion, a PE ratio of -17.15 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.49. The firm had revenue of $138.20 million during the quarter, compared to analysts’ expectations of $104.02 million. Blueprint Medicines had a negative net margin of 56.64% and a negative return on equity of 157.30%. The company’s revenue for the quarter was up 139.9% compared to the same quarter last year. During the same quarter last year, the company posted ($2.19) earnings per share. On average, equities research analysts anticipate that Blueprint Medicines will post -3.99 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Philina Lee sold 41,913 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the sale, the insider now owns 34,729 shares of the company’s stock, valued at $3,236,395.51. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Blueprint Medicines news, insider Philina Lee sold 41,913 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the transaction, the insider now directly owns 34,729 shares in the company, valued at $3,236,395.51. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Fouad Namouni sold 3,633 shares of the firm’s stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the sale, the insider now directly owns 69,070 shares in the company, valued at approximately $6,169,332.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.21% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Principal Financial Group Inc. grew its holdings in shares of Blueprint Medicines by 331.9% during the 1st quarter. Principal Financial Group Inc. now owns 62,670 shares of the biotechnology company’s stock valued at $5,945,000 after purchasing an additional 48,160 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of Blueprint Medicines during the first quarter worth $474,000. Vanguard Group Inc. increased its holdings in shares of Blueprint Medicines by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock worth $564,045,000 after buying an additional 147,827 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Blueprint Medicines in the 2nd quarter valued at $1,060,000. Finally, Comerica Bank boosted its holdings in shares of Blueprint Medicines by 2,582.9% during the 1st quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock valued at $1,028,000 after acquiring an additional 10,435 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.